Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
By
Yiska Weisblum,
Fabian Schmidt,
Fengwen Zhang,
Justin DaSilva,
Daniel Poston,
Julio C.C. Lorenzi,
Frauke Muecksch,
Magdalena Rutkowska,
Hans-Heinrich Hoffmann,
Eleftherios Michailidis,
Christian Gaebler,
Marianna Agudelo,
Alice Cho,
Zijun Wang,
Anna Gazumyan,
Melissa Cipolla,
Larry Luchsinger,
Christopher D Hillyer,
Marina Caskey,
Davide F Robbiani,
C.M. Rice,
Michel C Nussenzweig,
Theodora Hatziioannou,
Paul D Bieniasz
Posted 22 Jul 2020
bioRxiv DOI: 10.1101/2020.07.21.214759
(published DOI: 10.7554/elife.61312)
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes. ### Competing Interest Statement Patent applications submitted by Rockefeller University are pending for anti SARS-CoV-2 antibodies (MCN, DR, inventors) and VSV/SARS-CoV-2 chimeric virus (PDB, TH, FS and YW, inventors)
Download data
- Downloaded 14,453 times
- Download rankings, all-time:
- Site-wide: 470
- In microbiology: 54
- Year to date:
- Site-wide: 279
- Since beginning of last month:
- Site-wide: 860
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!